These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 27436202)

  • 1. Locoregional Recurrence Risk for Postmastectomy Breast Cancer Patients With T1-2 and One to Three Positive Lymph Nodes Receiving Modern Systemic Treatment Without Radiotherapy.
    Lai SF; Chen YH; Kuo WH; Lien HC; Wang MY; Lu YS; Lo C; Kuo SH; Cheng AL; Huang CS
    Ann Surg Oncol; 2016 Nov; 23(12):3860-3869. PubMed ID: 27436202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
    Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are there patients with T1 to T2, lymph node-negative breast cancer who are "high-risk" for locoregional disease recurrence?
    Mamtani A; Patil S; Stempel MM; Morrow M
    Cancer; 2017 Jul; 123(14):2626-2633. PubMed ID: 28334423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of molecular subtype on locoregional recurrence in mastectomy patients with T1-T2 breast cancer and 1-3 positive lymph nodes.
    Moo TA; McMillan R; Lee M; Stempel M; Ho A; Patil S; El-Tamer M
    Ann Surg Oncol; 2014 May; 21(5):1569-74. PubMed ID: 24488216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selecting breast cancer patients with T1-T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy.
    Truong PT; Olivotto IA; Kader HA; Panades M; Speers CH; Berthelet E
    Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1337-47. PubMed ID: 15817335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postmastectomy radiotherapy benefit in Chinese breast cancer patients with T1-T2 tumor and 1-3 positive axillary lymph nodes by molecular subtypes: an analysis of 1369 cases.
    Shen H; Zhao L; Wang L; Liu X; Liu X; Liu J; Niu F; Lv S; Niu Y
    Tumour Biol; 2016 May; 37(5):6465-75. PubMed ID: 26631044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.
    Yang TJ; Morrow M; Modi S; Zhang Z; Krause K; Siu C; McCormick B; Powell SN; Ho AY
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S495-501. PubMed ID: 26130454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selection criteria for postmastectomy radiotherapy in t1-t2 tumors with 1 to 3 positive lymph nodes.
    Moo TA; McMillan R; Lee M; Stempel M; Patil S; Ho A; El-Tamer M
    Ann Surg Oncol; 2013 Oct; 20(10):3169-74. PubMed ID: 23975289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is biological subtype prognostic of locoregional recurrence risk in women with pT1-2N0 breast cancer treated with mastectomy?
    Truong PT; Sadek BT; Lesperance MF; Alexander CS; Shenouda M; Raad RA; Taghian AG
    Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):57-64. PubMed ID: 24161421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postmastectomy radiotherapy improves disease-free survival of high risk of locoregional recurrence breast cancer patients with T1-2 and 1 to 3 positive nodes.
    He ZY; Wu SG; Zhou J; Li FY; Lin Q; Lin HX; Sun JY
    PLoS One; 2015; 10(3):e0119105. PubMed ID: 25781605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High expression of post-treatment Ki-67 status is a risk factor for locoregional recurrence following breast-conserving surgery after neoadjuvant chemotherapy.
    Yamazaki N; Wada N; Yamauchi C; Yoneyama K
    Eur J Surg Oncol; 2015 May; 41(5):617-24. PubMed ID: 25771264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal impact of postmastectomy radiation therapy on locoregional recurrence for breast cancer patients with 1 to 3 positive lymph nodes in the modern treatment era.
    Miyashita M; Tada H; Suzuki A; Watanabe G; Hirakawa H; Amari M; Kakugawa Y; Kawai M; Furuta A; Sato K; Yoshida R; Ebata A; Sasano H; Jingu K; Ohuchi N; Ishida T
    Surg Oncol; 2017 Jun; 26(2):163-170. PubMed ID: 28577722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of postmastectomy radiation on locoregional recurrence in breast cancer patients with 1-3 positive lymph nodes treated with modern systemic therapy.
    Tendulkar RD; Rehman S; Shukla ME; Reddy CA; Moore H; Budd GT; Dietz J; Crowe JP; Macklis R
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e577-81. PubMed ID: 22560546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Most Breast Cancer Patients with T1-2 Tumors and One to Three Positive Lymph Nodes Do Not Need Postmastectomy Radiotherapy.
    Muhsen S; Moo TA; Patil S; Stempel M; Powell S; Morrow M; El-Tamer M
    Ann Surg Oncol; 2018 Jul; 25(7):1912-1920. PubMed ID: 29564588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiotherapy can decrease locoregional recurrence and increase survival in mastectomy patients with T1 to T2 breast cancer and one to three positive nodes with negative estrogen receptor and positive lymphovascular invasion status.
    Yang PS; Chen CM; Liu MC; Jian JM; Horng CF; Liu MJ; Yu BL; Lee MY; Chi CW
    Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):516-22. PubMed ID: 19577858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic significance of the percentage of positive/dissected axillary lymph nodes in breast cancer recurrence and survival in patients with one to three positive axillary lymph nodes.
    Truong PT; Berthelet E; Lee J; Kader HA; Olivotto IA
    Cancer; 2005 May; 103(10):2006-14. PubMed ID: 15812825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Locoregional failure of postmastectomy patients with 1-3 positive axillary lymph nodes without adjuvant radiotherapy.
    Cheng JC; Chen CM; Liu MC; Tsou MH; Yang PS; Jian JJ; Cheng SH; Tsai SY; Leu SY; Huang AT
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(4):980-8. PubMed ID: 11958892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical value of adjuvant radiotherapy in patients with early stage breast cancer with 1 to 3 positive lymph nodes after mastectomy.
    Wu SG; He ZY; Li FY; Wang JJ; Guo J; Lin Q; Guan XX
    Chin J Cancer; 2010 Jul; 29(7):668-76. PubMed ID: 20591219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Locoregional recurrence risk factors and the impact of postmastectomy radiotherapy on patients with tumors 5 cm or larger.
    Nagao T; Kinoshita T; Tamura N; Hojo T; Morota M; Kagami Y
    Breast Cancer; 2014 May; 21(3):292-301. PubMed ID: 22890603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indications for Postmastectomy Radiation After Neoadjuvant Chemotherapy in ypN0 and ypN1-3 Axillary Node-Positive Women.
    Fowble B; Jairam AK; Wang F; Peled A; Alvarado M; Ewing C; Esserman L; Park C; Lazar A
    Clin Breast Cancer; 2018 Feb; 18(1):e107-e113. PubMed ID: 28830795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.